^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Ambezhu (bevacizumab biosimilar)

    i
    Other names: SCT510, SCT 510
    Associations

    News

    Trials
    Company:
    Sinocelltech
    Drug class:
    VEGF-A inhibitor
    Related drugs:
    Associations

    News

    Trials
    almost2years
    SCT-I10A Plus SCT510 Versus Sorafenib as First-Line Therapy for Advanced Hepatocellular Carcinoma (clinicaltrials.gov)
    P2/3, N=405, Active, not recruiting, Sinocelltech Ltd. | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    sorafenib • Ambezhu (bevacizumab biosimilar) • Anyouping (finotonlimab)